Table 1.
Baseline patient characteristics (n = 20)
| Parameter | |
|---|---|
|
Age [median, years] |
61 (range 46–78) |
| Sex | |
| Male | 13 (65%) |
| Female | 7 (35%) |
| UICC stage | |
| III | 2 (10%) |
| IV A | 4 (20%) |
| IV B | 14 (70%) |
| Progression-free survival [median, months] | |
| FOLFIRINOX | 8.0 |
| Gem/nab-Pac | 6.0 |
| All patients | 8.0 |
| Overall survival [median, months] | |
| FOLFIRINOX | 16.0 |
| Gem/nab-Pac | 14.0 |
| All patients | 14.0 |
| ECOG | |
| 0–1 | 19 (95%) |
| 3 | 1 (5%) |
| Localization of distant metastases | |
| Liver | 10 (50%) |
| Non-liver | 3 (15%) |
| Liver and further location | 1 (5%) |
| Histology | |
| Adenocarcinoma | 19 (95%) |
| MANEC | 1 (5%) |
| Chemotherapy regimen | |
| FOLFIRINOX | 17 (85%) |
| Gem/nab-Pac | 3 (15%) |
| Surgical therapy prior to inclusion in study | |
| Yes | 10 (50%) |
| No | 10 (50%) |
UICC Union for International Cancer Control, ECOG Eastern Cooperative Oncology Group, MANEC mixed adenoneuroendocrine carcinoma